Orchid Pharma Limited

NSEI:ORCHPHARMA Voorraadrapport

Marktkapitalisatie: ₹70.5b

Orchid Pharma Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Orchid Pharma has been growing earnings at an average annual rate of 74.1%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 22.7% per year. Orchid Pharma's return on equity is 9.6%, and it has net margins of 12.7%.

Belangrijke informatie

74.1%

Groei van de winst

116.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie17.5%
Inkomstengroei22.7%
Rendement op eigen vermogen9.6%
Nettomarge12.7%
Volgende winstupdate14 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%

Jul 29
Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%

We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Jun 12
We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

May 08
Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Feb 28
Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Feb 06
Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Dec 18
Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Opbrengsten en kosten

Hoe Orchid Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NSEI:ORCHPHARMA Opbrengsten, kosten en inkomsten (INR Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 248,8091,1217880
31 Mar 248,1949227300
31 Dec 238,1221,2467030
30 Sep 237,5131,0276780
30 Jun 237,1787756800
31 Mar 236,6595316640
31 Dec 226,341-1756460
30 Sep 226,357-3566540
30 Jun 225,982-4716430
31 Mar 225,596-6046490
31 Dec 215,010-5926060
30 Sep 214,424-9346230
30 Jun 214,232-1,0096550
31 Mar 214,501-9526860
31 Dec 204,420-1,3078820
30 Sep 204,687-1,1368000
30 Jun 204,918-1,1538140
31 Mar 204,838-6978630
31 Mar 196,0006949450
31 Mar 186,830-3,5289840
31 Mar 177,965-4,9549210
31 Mar 168,734-2,7919880
31 Mar 1511,644-1,3111,3970

Kwaliteitswinsten: ORCHPHARMA has high quality earnings.

Groeiende winstmarge: ORCHPHARMA's current net profit margins (12.7%) are higher than last year (10.8%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ORCHPHARMA has become profitable over the past 5 years, growing earnings by 74.1% per year.

Versnelling van de groei: ORCHPHARMA's earnings growth over the past year (44.6%) is below its 5-year average (74.1% per year).

Winst versus industrie: ORCHPHARMA earnings growth over the past year (44.6%) exceeded the Pharmaceuticals industry 19.1%.

Rendement op eigen vermogen

Hoge ROE: ORCHPHARMA's Return on Equity (9.6%) is considered low.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y